MiR-124 regulated genes and pathways as targets for therapeutic intervention
The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-124, using miR-124 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.
1. A method of inhibiting proliferation of a prostate or liver cancer cell comprising administering to a subject having a prostate cancer or liver cancer cell an isolated nucleic acid comprising a miR-124 nucleic acid sequence in combination with an isolated nucleic acid comprising a miR-34a, let-7b, let-7c, or let-7g nucleic acid sequence in an amount sufficient to inhibit proliferation of the prostate or liver cancer cell.
2. The method of claim 1 , wherein the prostate carcinoma is associated with detectable prostate-specific antigen (PSA).
3. The method of claim 1 , wherein the prostate carcinoma is androgen independent.
4. The method of claim 1 , wherein the liver carcinoma is hepatoma, hepatocarcinoma or an hepatic adenocarcinoma.
5. The method of claim 1 , wherein the liver carcinoma is hepatoblastoma, or a cholangiocarcinoma.
6. The method of claim 1 , wherein the isolated miR-124, miR-34a, let-7b, let-7c, or let-7g nucleic acid is a recombinant nucleic acid.
7. The method of claim 1 , wherein the miR-124, miR-34a, let-7b, let-7c, or let-7g nucleic acid is a synthetic nucleic acid.
8. The method of claim 1 , wherein the nucleic acid is administered enterally or parenterally.
9. The method of claim 1 , wherein the nucleic acid is comprised in a pharmaceutical formulation.
10. The method of claim 9 , wherein the pharmaceutical formulation is a lipid composition or a nanoparticle composition.
11. The method of claim 9 , wherein the pharmaceutical formulation consists of biocompatible and biodegradable molecules.